Biomonadic is at the forefront of advancing gene therapy process optimization and longevity therapies through innovative technologies. The company focuses on reimagining cell culture bioprocesses, particularly in the production of Klotho anti-aging plasmid and protein therapies. By leveraging reinforcement learning and the Internet of Things (IoT), Biomonadic has developed a real-time data platform that integrates all relevant data involved in cell culture. This platform utilizes AI-based analysis tools to customize manufacturing protocols, thereby optimizing processes for improved quality, growth, and yield. The incorporation of IoT sensors within bioreactors allows for the collection of real-time timeseries data, facilitating automated data collection and characterization of bioprocesses on a minute-by-minute basis.

In addition to real-time data collection, Biomonadic emphasizes the importance of batch records management, providing a comprehensive interface for accessing all documents and records associated with manufacturing runs. This holistic approach ensures that all information related to cell culture bioprocesses is centralized for easy analysis and optimization. The company’s hybrid methodology combines AI techniques with biological manufacturing datasets, enabling faster production of higher-quality therapies at reduced costs. By partnering with leading cell therapy bioreactor manufacturers, Biomonadic aims to integrate its software capabilities with advanced hardware, further enhancing its ability to optimize bioprocesses and accelerate the transition from research and development to production.

United States

Biomonadic is an early stage techbio startup leveraging AI and IoT to resolve critical supply chain bottlenecks affecting the cell and gene therapy (CGT). They are creating a next generation AI empowered data platform for biotech manufacturing, leveraging reinforcement learning and LLMs to augment their capabilities.

Biomonadic

Company Details